Codexis Inc
NASDAQ:CDXS

Watchlist Manager
Codexis Inc Logo
Codexis Inc
NASDAQ:CDXS
Watchlist
Price: 4.61 USD 6.47% Market Closed
Market Cap: 375.2m USD
Have any thoughts about
Codexis Inc?
Write Note

Codexis Inc
Short-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Codexis Inc
Short-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
Codexis Inc
NASDAQ:CDXS
Short-Term Investments
$52.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Short-Term Investments
$2B
CAGR 3-Years
N/A
CAGR 5-Years
210%
CAGR 10-Years
51%
Danaher Corp
NYSE:DHR
Short-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mettler-Toledo International Inc
NYSE:MTD
Short-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Agilent Technologies Inc
NYSE:A
Short-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
IQVIA Holdings Inc
NYSE:IQV
Short-Term Investments
$140m
CAGR 3-Years
10%
CAGR 5-Years
20%
CAGR 10-Years
4%
No Stocks Found

Codexis Inc
Glance View

Market Cap
375.1m USD
Industry
Life Sciences Tools & Services

Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. The company is headquartered in Redwood City, California and currently employs 261 full-time employees. The company went IPO on 2010-04-22. The firm is engaged in discovering, developing and sells enzymes and other proteins. The company operates through two segments: Performance Enzymes and Novel Biotherapeutics. The Company’s CodeEvolver technology platform accelerates biologic discovery through the transformation of a starting enzyme into a biocatalyst or therapeutic candidate. The firm has commercialized its CodeEvolver protein engineering technology platform and products in the pharmaceutical’s markets. Its products include biocatalysts, chemical intermediates and Codex biocatalyst panels and kits. The company also commercialized three additional enzymes, such as Codex HiFi DNA Polymerase for use in next generation sequencing, Codex HiTemp Reverse Transcriptase for use in molecular diagnostic applications, and Codex HiCap RNA Polymerase for use in RNA synthesis applications. The firm is developing its lead program, CDX-6114 for the treatment of hyperphenylalaninemia (HPA).

CDXS Intrinsic Value
2.92 USD
Overvaluation 37%
Intrinsic Value
Price

See Also

What is Codexis Inc's Short-Term Investments?
Short-Term Investments
52.8m USD

Based on the financial report for Sep 30, 2024, Codexis Inc's Short-Term Investments amounts to 52.8m USD.

Back to Top